What is the role of stem cell transplantation (SCT) in the treatment of Burkitt lymphoma/Burkitt-like lymphoma (BL/BLL)?

Updated: Dec 20, 2019
  • Author: Ali H Kanbar, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

The use of high-dose chemotherapy plus stem cell transplantation (SCT) has decreased because of the high rate of remission achieved with current treatment regimens.

High-dose chemotherapy plus autologous SCT may be considered for patients whose condition has not responded to (primary refractory) or who have relapsed after first-line conventional chemotherapy. The outcome for adult patients treated with a short, intensive regimen is less favorable than the outcome in children. Up to 40% of the patients treated on the LMB81 and LMB84 regimens experienced relapse; this rate is lower in patients treated with CODOX-M/IVAC (cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate / ifosfamide, etoposide, high-dose cytarabine). [29] Current indications for treatment of these patients with high-dose chemotherapy plus autologous SCT remain similar to those of the pediatric group.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!